HR Execs on the Move

Atara Biotherapeutics

www.atarabio.com

 
Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or ...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.atarabio.com
  • 611 Gateway Boulevard Suite 900
    South San Francisco, CA USA 94080
  • Phone: 650.278.8930

Executives

Name Title Contact Details
Christopher Haqq
Executive Vice President of Research and Development and Chief Scientific Officer Profile
Maribel Hines
Vice President, Talent, Culture and Inclusion Profile

Similar Companies

Rheos Medicines

A new setpoint for immunometabolism

Provident Clinical Research and Consulting

Provident Clinical Research & Consulting is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Celula Inc

Celula Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharmaceutical Product Development

The Pharmaceutical Product Development, LLC is a global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services.

Emulate

We work at the intersection of biology, engineering, and design, developing technologies that emulate human biology. Our products are enabling a new era of precision medicine and the development of applications for personalized health. Our Human Emulation System, which uses Organs-on-Chips technology, is being used by industry, government, and academia to understand how different diseases, medicines, chemicals and foods affect human health. The system offers researchers a new standard for predicting human response — with greater precision and control than today`s cell culture or animal-based experimental methods. We are also leading a bold, new precision medicine initiative with our clinical partners. Named "Patient-on-a-Chip," the program is developing personalized chips with patients` own cells. This initiative will help transform the way each of us understands our own bodies and manages our own health. Research conducted using our Organ-Chips has been published in high-impact scientific journals, including Science. In addition, Organ-Chips have been acquired by the Museum of Modern Art (MoMA) in New York for their permanent collection, and have also been awarded Product Design of the Year 2015 by London`s Design Museum. Our founding team pioneered the original Organs-on-Chips technology during their residency within the Wyss Institute for Biologically Inspired Engineering at Harvard University.